The End of My Addiction

(Ameisen, 2005). At a behavioural level, alcohol, baclofen and GHB all share sedative/hypnotic effects in humans. Clinical trials have shown baclofen to reduce anxiety in alcoholic (Krupitsky et al ., 1993; Addolorato et al ., 2002) and non-alcoholic (Breslow et al ., 1989; Drake et al ., 2003) patients alike. And somnolence is an overwhelmingly prevalent side effect of baclofen. Yet unlike other sedative/hypnotics (benzodiazepines, meprobamate, barbiturates), baclofen and GHB have been specifically shown to reduce craving in alcoholic patients (Addolorato et al ., 2002; Caputo et al ., 2003; Nava et al ., 2006). In animals, effects of baclofen on anxiety are more heterogeneous. While some studies demonstrate that baclofen has sedative activity (Carai et al ., 2004), lack of anxiolytic activity (Dalvi and Rodgers, 1996) and even anxiogenic actions (Car and Wisniewska, 2006) have also been reported. Also, while there are reports showing baclofen to increase severity of alcohol withdrawal in animals (Humeniuk et al ., 1994), the efficacy of baclofen in the treatment of acute withdrawal syndrome has been shown to be comparable to that of diazepam in clinical trials (Addolorato et al ., 2006). In mice, Carai et al. established that the sedative/hypnotic effect of GHB is, like that of baclofen, mediated by the stimulation of GABA B receptors (Carai et al ., 2001) which adds support to the hypothesis that the GABA B receptor constitutes a central site of action of GHB. Functionally, both baclofen and GHB increase a potassium current and decrease the H-current in hippocampal neurons via GABA B receptor (Schweitzer et al ., 2004). Of alcohol, GHB and baclofen, only one is a naturally occurring molecule: GHB. This leads me to raise the hypothesis that a primary dysfunction in GHB, such as a quantitative or functional deficit, could be partly responsible for the dysphoric syndrome (anxiety, insomnia, muscular tension…) that precedes and later coexists with alcohol dependence. And that baclofen effect could compensate for some of the deficit of GABA B -mediated effect of GHB, and suppress dysphoria and dependence. Most sedative/hypnotics can cause dependence. In clinical practice, of these two agents that stimulate GABA B receptors, GHB causes dependence, while dependence has not been reported with baclofen. This could be related to GHB’s many sites of action aside from GABA B . Animal studies should be performed to test this hypothesis. Of interest, a GHB receptor has recently [been] characterized in the human brain.
    References
    Addolorato, G., Caputo, F., Capristo, E. et al . (2002) Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol and Alcoholism 37 , 504–508.
    Addolorato, G., Leggio, L., Abenavoli, L. et al . (2006) Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. American Journal of Medicine 119 , 276.e13–8.
    Ameisen, O. (2005) Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol and Alcoholism 40 , 147–150.
    Andriamampandry, C., Taleb, O., Kemmel, V. et al . (2007) Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. FASEB J. 3 , 885–895.
    Breslow, M. F., Fankhauser, M. P., Potter, R. L. et al . (1989) Role of gamma-aminobutyric acid in antipanic drug efficacy. American Journal of Psychiatry 146 , 353–356.
    Bucknam, W. (2007) Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol and Alcoholism 42 , 158–160.
    Caputo, F., Addolorato, G. and Lorenzini, F. (2003) Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug and Alcohol Dependence 70 , 85–91.
    Car, H. and Wisniewska, R. J. (2006) Effects of baclofen and L-AP4 in passive avoidance test in rats after hypoxia-induced amnesia. Pharmacological Reports 58 , 91–100.
    Carai, M. A., Colombo, G., Brunetti, G. et al . (2001) Role of GABA B receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. European Journal of Pharmacology 428 , 315–321.
    Carai, M. A., Vacca, G., Serra, S. et al . (2004) Suppression of GABA B receptor function in vivo by disulfide reducing agent, DL-dithiothreitol (DTT). Psychopharmacology 174 , 283–290.
    Dalvi, A. and Rodgers, R. J. (1996) GABAergic